Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Cagrilintide.

Research draft

Cagrilintide is a long-acting amylin analogue studied for weight management.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Cagrilintide is a long-acting amylin analogue studied for weight management.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFOLong-acting amylin analogue
PRIMARY CONTEXTAmylin receptor agonist

Mechanism

It engages amylin-related receptors involved in satiety and food intake.

Human research

Randomised subcutaneous trials support weight-loss activity. Combination results with semaglutide must be distinguished from cagrilintide alone.

Preclinical & other research

Receptor and animal experiments support the satiety rationale but do not establish clinical outcomes.

Safety & unknowns

Gastrointestinal symptoms are important tolerability issues; long-term assessment is specific to the studied formulation.

Regulatory status

Clinical-development medicine in the sources reviewed; combination and monotherapy approvals require separate checks.

Reported use & evidence

Research profile draft

The supplied Cagrilintide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds